Prevalence and associated factors of dysphagia in chronic obstructive pulmonary disease patients: A systematic review and meta-analysis.

Heart LungMay 4, 2026 (epub)
Clinical ResearchPulmonology

Yang Yang, Hong Yan, Lin Zhao et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the prevalence and associated factors of dysphagia in patients with chronic obstructive pulmonary disease (COPD). Analyzing 18 studies with 4608 patients, the overall prevalence of dysphagia was found to be 38.2% (95% CI: 29.8%-46.6%). The study highlights various risk factors linked to dysphagia in this population.

Key findings

  • The overall prevalence of dysphagia in COPD patients was 38.2% (95% CI: 29.8%-46.6%).
  • Dysphagia occurrence was associated with age (OR=1.18) and mMRC dyspnea grade (OR=1.69).
  • A higher number of missing teeth (≥6) was linked to increased dysphagia risk (OR=2.63).
  • The use of non-invasive mechanical ventilation was associated with lower odds of dysphagia (OR=0.40).

Why it matters

Understanding the prevalence and risk factors of dysphagia in COPD patients is crucial for healthcare professionals to develop targeted interventions. This can enhance patient management and improve quality of life by addressing swallowing difficulties.

Source

PubMed · PMID 42085928

Published in Heart Lung. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pulmonology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.